Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis
Status:
Terminated
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effectiveness of giving patients who have been
newly diagnosed with untreated early stage primary myelofibrosis (PMF) a study drug called
PEGINTRON (also known as pegylated interferon alfa 2b). This intervention will be compared to
the widely employed "watch and wait" (best supportive care) approach for early stage PMF, in
which patients are followed closely and treatment initiated only if the disease progresses.